GLSI-100 Shows 83% Reduction in Breast Cancer Recurrence in Phase III FLAMINGO-01 Open Label Arm
GLSI has more than doubled off its 52-week low of $7.78.
Summary
Greenwich LifeSciences provided a preliminary update on the open-label non-HLA-A*02 arm of its Phase III FLAMINGO-01 trial for GLSI-100, an immunotherapy to prevent breast cancer recurrence. The update, based on six additional months of patient data, shows a continued reduction in recurrence rate to less than 1% per year. This represents an 83% statistically significant reduction (p < 0.005) compared to the 4% annual recurrence rate observed in a similar population from the Katherine study (Kadcyla arm). This follows a previous significant update on the FLAMINGO-01 trial announced on March 3, 2026, indicating ongoing positive data flow from the pivotal study. The strong preliminary efficacy data, showing an 83% reduction in recurrence rate, is highly positive for GLSI-100 and significantly de-risks the trial. For a clinical-stage biopharmaceutical company, such results from a Phase III trial are a major catalyst and could lead to substantial stock appreciation. Investors will monitor future updates, including final results and presentations at upcoming conferences, as well as the progress of the blinded, placebo-controlled arm of the trial.
At the time of this announcement, GLSI was trading at $29.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $389.7M. The 52-week trading range was $7.78 to $34.10. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.